Epidemiology and Economic Burden of IPF and PPF
Anna Podolanczuk, M.D., M.S., discusses how key epidemiological trends in idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF), including changes in incidence and prevalence, contribute to the growing economic burden that patients with these conditions face.
Video content above is prompted by the following:
- What are the key epidemiological facts about IPF and PPF, and how have the incidence and prevalence changed over time?
- Describe the economic burden for IPF and PPF that most patients are faced with.
Examining Health Equity Among Different Racial and Ethnic Subpopulations With Multiple Sclerosis
March 15th 2021Multiple sclerosis (MS) is a chronic disease that involves demyelination of plaque throughout the white and gray matter of the central nervous system. The early stages of MS are usually marked by a relapsing-remitting course of neurological deficits, which progress toward continuous, permanent dysfunction and disability. Of those with a diagnosis of MS, 74% are women.
Read More
Improving Ophthalmic Care Access and Treatment Among Aging Adults
August 20th 2020As the American population ages, chronic conditions are becoming an increasing challenge for payers. In addition to conditions such as cardiovascular disease and diabetes, eye disease is also prevalent among aging adults.
Read More
